IBRX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -8.80. Updated 2026-07-23.
ImmunityBio (IBRX) Research Hub
ImmunityBio (IBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.91 USD (-1.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.80, market cap 7.99B. This hub links to the full technical, earnings and options research available for IBRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.91 USD (-1.86%) |
| 52-week range | 6.65 USD – 9.6 USD |
| Trend regime | Range |
| 14-day RSI | 54.9 (Neutral) |
| Trailing P/E | -8.80 |
| Market cap | 7.99B |
| Dividend yield | 0.00% |
Available research for IBRX
Covered Call on IBRX: how it works, illustrative setup around the real 7.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IBRX: how it works, illustrative setup around the real 7.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IBRX: how it works, illustrative setup around the real 7.91 USD price, max profit/loss, breakeven and when to use it. Educational.
IBRX technical analysis: range, last 7.91 USD, RSI 54.9, 52w range 6.65 USD–9.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IBRX in?
ImmunityBio (IBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IBRX in an uptrend or downtrend?
As of 2026-09-11, IBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IBRX's trailing P/E ratio?
IBRX's trailing P/E is -8.80, with a market cap of 7.99B. See the earnings research page for full valuation detail.